Dr Andrew Chantry
Department of Oncology and Metabolism
Senior Clinical Lecturer
+44 114 215 9003
Full contact details
Department of Oncology and Metabolism
The Medical School
Beech Hill Road
Dr Andy Chantry is a Senior Clinical Lecturer in the Dept of Oncology, University of Sheffield and leads the Sheffield Myeloma Research Team (SMaRT). He is also an Honorary Consultant Haematologist in the Dept of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust.
Since appointment in 2012, he has been awarded over £1.5million in research grants, notably from Leukaemia and Lymphoma Research. He has also received substantial industry sponsorship and access to novel compounds from Celgene, Acceleron, Novartis and Amgen.
- Research interests
His principal research interests are anabolic strategies in the treatment of myeloma bone disease and novel strategies to target myeloma tumour. He also has holistic research interests including life with cancer – holistic care and quality of life studies, computational modeling of cancer including using digital simulations and game technology.
- Mechanisms and treatment of bone pain in multiple myeloma. Current Opinion in Supportive and Palliative Care, 13(4), 408-416.
- A university – Led initiative to promote voluntary non-remunerated blood donation in a developing country. Transfusion and Apheresis Science, 58(5), 674-679.
- TGFβ inhibition stimulates collagen maturation to enhance bone repair and fracture resistance in a murine myeloma model. Journal of Bone and Mineral Research. View this article in WRRO
- Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. Journal of Bone Oncology, 17, 100243-100243.
- Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter‐laboratory study: Is it ready for primetime use?. Cytometry Part B: Clinical Cytometry, 96(3), 201-208.
- Knowledge, attitudes and risk perception surrounding blood transfusion in Trinidad and Tobago. ISBT Science Series, 14(2), 201-207.
- Myeloma-Specific Oncolytic Adenovirus Induces Significant Tumour Oncolysis In Vitro and In Vivo and Prevents Cell Line Regrowth. Blood, 132(Supplement 1), 3213-3213.
- Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models. Journal of Bone and Mineral Research. View this article in WRRO
- Bone Research Society Abstracts. JBMR Plus, 2(S1), S1-S50.
- ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.. PLoS One, 13(6). View this article in WRRO
- New agents in the Treatment of Myeloma Bone Disease. Calcified Tissue International, 102(2), 196-209. View this article in WRRO
- Mesenchymal lineage cells and their importance in B lymphocyte niches. Bone. View this article in WRRO
- SAHA-induced TRAIL-sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture. Experimental Cell Research, 360(2), 226-235.
- The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1‐Fluoro‐2‐(Imidazo‐[1,2‐α]Pyridin‐3‐yl)‐Ethyl‐Bisphosphonate). Journal of Bone and Mineral Research, 32(9), 1860-1869. View this article in WRRO
- A follow-up survey of knowledge, attitudes and practices surrounding blood donation in Trinidad and Tobago. ISBT Science Series, 12(3), 349-356.
- Guidelines for the use of imaging in the management of patients with myeloma. British Journal of Haematology, 178(3), 380-393.
- Comparison of the CELLEX™ and UVAR-XTS™ closed-system extracorporeal photopheresis devices in the treatment of chronic graft-versus-host disease. Journal of Clinical Apheresis.
- Low-dose methotrexate in myeloproliferative neoplasm models.. Haematologica, 102, e336-e339. View this article in WRRO
- Blood donors' attitudes towards voluntary non-remunerated donation in Trinidad and Tobago. Transfusion Medicine.
- Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods. Bone, 83, 9-16.
- Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model. British Journal of Haematology, 172(1), 64-79.
- Time to redefine Myeloma. British Journal of Haematology, 171(1), 1-10.
- Development of a Trojan horse oncolytic virus for treatment of myeloma.. Journal of Clinical Oncology, 33(15_suppl), e14035-e14035.
- The application of antibotoxsome, a novel cytotoxic conjugate, in cell death in in vitro models of pancreatic, liver, breast, cervical cancer, and myeloma.. Journal of Clinical Oncology, 33(15_suppl), e12018-e12018.
- A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease. Bone, 77, 57-68.
- Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma. British Medical Bulletin, 113(1), 15-30.
- Researching surviving cancer and sexuality using visual methods: a reflection on research rationale and negotiating ethical issues. Families, Relationships and Societies, 4(3), 483-492.
- Myeloma bone disease: pathogenesis, current treatments and future targets. British Medical Bulletin, 111(1), 117-138.
- Erratum: Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of Bone and Mineral Research, 27(9), 2038-2038.
- A small molecule modulator of prion protein increases human mesenchymal stem cell lifespan, ex vivo expansion, and engraftment to bone marrow in NOD/SCID mice.. Stem Cells, 30(6), 1134-1143.
- Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo.. PLoS One, 7(5), e35830. View this article in WRRO
- Erratum: Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo (Journal of Bone and Mineral Research (2010) 25:12 (2633-2646) DOI:10.1002/jbmr.142). Journal of Bone and Mineral Research, 27(9), 2036-2037.
- Spontaneous splenic rupture: an unusual presentation of CML. Case Reports, 2011(mar16 1), bcr0220113879-bcr0220113879.
- Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.. J Bone Miner Res, 25(12), 2633-2646.
- A systems biology approach to Down syndrome: identification of Notch/Wnt dysregulation in a model of stem cells aging.. Biochim Biophys Acta, 1792(4), 353-363.
- Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.. J Bone Miner Res, 24(3), 425-436.
- Inhibiting Dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma. CALCIFIED TISSUE INT, 83(1), 6-6.
- Apomine™, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. International Journal of Cancer, 120(8), 1657-1663.
- Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.. Biol Blood Marrow Transplant, 12(12), 1310-1317.
- Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. British Journal of Haematology, 135(5), 688-692.
- NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease. PLOS ONE, 10(3), e0119546-e0119546. View this article in WRRO
- Antiresorptives, The Duration and Safety of Osteoporosis Treatment (pp. 17-36). Springer International Publishing
- Myeloma bone disease – pathogenesis of bone destruction and therapeutic strategies, Myeloma (pp. 96-109). Cambridge University Press
Conference proceedings papers
- Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018. Blood, Vol. 132(Supplement 1) (pp 4743-4743)
- Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the development of osteolytic bone disease in the 5T2MM murine model of myeloma. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 153 (pp 7-7)
- Targeting tumour-initiating cells with trail based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. BONE, Vol. 48(1) (pp S15-S15)
- Inhibiting glycogen synthase kinase-3 (GSK-3) prevents the development of myeloma bone disease. BONE, Vol. 44 (pp S53-S54)
- Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the formation of osteolytic bone disease in the 5T2MM murine model of myeloma. Bone, Vol. 44 (pp S55-S55)
- P3. A soluble activin type II receptor prevents the development of myeloma bone disease. Cancer Treatment Reviews, Vol. 34 (pp 13-14)
- OC7. Inhibiting dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma. Cancer Treatment Reviews, Vol. 34 (pp 52-52)
- A soluble activin type II receptor prevents myeloma bone disease. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1118-1118)
- Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukaemia in second remission: a British Society of Bood and Marrow Transplantation Registry study. BONE MARROW TRANSPLANTATION, Vol. 37 (pp S9-S10)
- Teaching activities
He lectures on the undergraduate MB ChB course and informally conducts postgraduate teaching of junior doctors and haematology trainees. He is a contributor to MSc in Translational Oncology and the MSc in Health Care Studies.
- Professional activities
Nationally, he is an executive member of the NCRI Myeloma Sub-Group, through which all significant UK Myeloma Clinical Trials are administered. He is also an executive member of the United Kingdom Myeloma Forum, the national body for Haematologists leading clinical and research led developments in the UK. He is a member of the UKMF National Guidelines Group with a special interest in Myeloma Bone Disease.
Locally, he is an executive member of the local Cancer Clinical Trial Executive Committee and a member of the Sheffield Experimental Cancer Medicine Centre. He is a member of the Mellanby Centre for Bone Oncology and Insigneo, the Centre for in Silico Medical Research.